They showed that knockdown of CALCRL in human AML cell lines (that were different from the ones we had used) decreased proliferation, increased apoptosis, and enhanced cellular sensitivity to araC and idarubicin (Figure 3). This evidence concerns the gene CALCRL and acute myeloid leukemia.